Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Feb 1;5(2):181-186.
doi: 10.1001/jamaoncol.2018.4270.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women

Affiliations
Comparative Study

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women

Megan A Clarke et al. JAMA Oncol. .

Abstract

Importance: As cervical cancer screening transitions to primary human papillomavirus (HPV) testing, effective triage and management of HPV-positive women is critical to avoid unnecessary colposcopy referral and associated harms while maintaining high sensitivity for cervical precancer. Triage with p16/Ki-67 dual-stain (DS) testing has shown high sensitivity and specificity for detection of cervical precancers; however, longitudinal studies are needed to determine the long-term risk of precancer following a negative DS result.

Objective: To evaluate the longitudinal performance of p16/Ki-67 DS triage for detection of cervical precancer in HPV-positive women over 5 years of follow-up in the context of clinical management thresholds.

Design, setting, and participants: Prospective cohort study of HPV-positive women 30 years or older undergoing routine cervical cancer screening in 2012 with HPV and Papanicolaou (hereinafter "cytology") co-testing within the Kaiser Permanente Northern California health care system. Follow-up of medical records was conducted through 2017.

Exposures: All p16/Ki-67 DS testing was performed on residual SurePath material, and slides were evaluated for p16/Ki-67 positivity.

Main outcomes and measures: Histological end points were ascertained from the clinical database through 2017. We estimated 5-year cumulative risks of cervical intraepithelial neoplasia grades of 2 or worse (≥CIN2) or grades 3 or worse (≥CIN3) by baseline DS and cytology at yearly intervals using Logistic Weibull models. Risks were compared with clinical management thresholds for colposcopy referral and a 1-year return interval.

Results: Among the 1549 HPV-positive women in this study, the mean age at enrollment was 42.2 years, and the median follow-up time was 3.7 years (range, 0.2-5.4 years). Positive DS results were associated with significantly higher cumulative 5-year risks of ≥CIN2 compared with abnormal cytology (31.0%; 95% CI, 27.2%-35.3% vs 25.0%; 95% CI, 21.7%-28.7%; P = .03). Women with DS-negative findings had significantly lower 5-year risks of ≥CIN2 compared with women with normal cytology (8.5%; 95% CI, 6.5%-11.1% vs 12.3%; 95% CI, 9.8%-15.4%; P = .04). In DS-negative women, the risks of both ≥CIN2 and ≥CIN3 remained below the colposcopy referral threshold for all 5 years, crossing the 1-year return threshold at 3 years.

Conclusions and relevance: Triage with p16/Ki-67 DS provides better long-term risk stratification than cytology over 5 years. The low risk of cervical precancer in p16/Ki-67 DS-negative women permits safe extension of follow-up intervals for 3 years.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Schiffman and Wentzensen are employed by the National Cancer Institute (NCI), and the NCI has received cervical cancer screening assays in kind or at reduced cost from Becton, Dickinson and Company and Roche for studies that Drs Schiffman and Wentzensen are working on. Dr Castle has received commercial HPV tests for research at reduced or no cost from Roche, Arbor Vita Corporation, and Cepheid. No other disclosures are reported.

Figures

Figure 1.
Figure 1.. Study Population Enrollment Flow Diagram
Women missing follow-up data and those with baseline positive co-test results and/or other positive follow-up screening results without a colposcopy visit were considered indeterminate for the presence or absence of disease (n = 121). DS indicates p16/Ki-67 dual-stain testing; CIN2, cervical intraepithelial neoplasia grade of 2; CIN3, CIN grade of 3; Pap, Papanicolaou cytology testing.
Figure 2.
Figure 2.. Cumulative Risk of ≥CIN2 and ≥CIN3 by p16/Ki-67 Dual-Stain Testing (DS) and Papanicolaou Cytology (Pap) Results
The 5-year cumulative risk curves were generated using the logistic Weibull model. The dashed line corresponds to the threshold for a 1-year return, and the dotted line corresponds to the threshold for immediate colposcopy referral in this study population. Plus sign indicates positive; minus sign, negative; ASC-US atypical squamous cells of undetermined significance; CIN2, cervical intraepithelial neoplasia grade of 2; CIN3, CIN grade of 3; NILM, negative for intraepithelial lesion or malignancy.
Figure 3.
Figure 3.. Cumulative Risk of ≥CIN2 and ≥CIN3 by Combined Categories of p16/Ki-67 Dual-Stain Testing (DS) and Papanicolaou Cytology (Pap) Results
The 5-year cumulative risk curves were generated using the logistic Weibull model. The dashed line corresponds to the threshold for a 1-year return, and the dotted line corresponds to the threshold for immediate colposcopy referral in this study population. Plus sign indicates positive; minus sign, negative; ASC-US, atypical squamous cells of undetermined significance; CIN2, cervical intraepithelial neoplasia grade of 2; CIN3, CIN grade of 3; NILM, negative for intraepithelial lesion or malignancy.

References

    1. Cuschieri K, Ronco G, Lorincz A, et al. . Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018;143(4):735-745. doi:10.1002/ijc.31261 - DOI - PubMed
    1. Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76(suppl 1):S49-S55. doi:10.1016/j.jcv.2015.11.015 - DOI - PMC - PubMed
    1. Wentzensen N, Arbyn M, Berkhof J, et al. . Eurogin 2016 roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2017;140(10):2192-2200. doi:10.1002/ijc.30579 - DOI - PubMed
    1. Saslow D, Solomon D, Lawson HW, et al. . American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16(3):175-204. doi:10.1097/LGT.0b013e31824ca9d5 - DOI - PMC - PubMed
    1. Benevolo M, Allia E, Gustinucci D, et al. ; New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group . Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women. Cancer Cytopathol. 2017;125(3):212-220. doi:10.1002/cncy.21800 - DOI - PubMed

Publication types

MeSH terms